NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $8.53 0.00 (0.00%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Xeris Biopharma Stock (NASDAQ:XERS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xeris Biopharma alerts:Sign Up Key Stats Today's Range$8.38▼$8.5950-Day Range$7.36▼$8.9452-Week Range$5.25▼$10.08Volume1.03 million shsAverage Volume1.49 million shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas. The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S. Food and Drug Administration for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes. Gvoke is the first and only ready-to-use glucagon rescue product, offering rapid emergency treatment without the time-consuming reconstitution steps required by traditional glucagon kits. In addition to Gvoke, Xeris is advancing a pipeline of liquid-stable therapies, including investigational rescue treatments for seizures and other acute conditions. Founded in 2008 and headquartered in Chicago, Illinois, Xeris Biopharma operates primarily in the United States while exploring international partnerships to expand the reach of its novel drug-delivery technologies. The company is led by President and Chief Executive Officer Paul Edick, whose leadership has guided Xeris from its early research stages through the commercialization of its first product. As Xeris continues to grow its portfolio, it aims to address unmet needs across a spectrum of endocrine and neurology indications.AI Generated. May Contain Errors. Read More Xeris Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreXERS MarketRank™: Xeris Biopharma scored higher than 76% of companies evaluated by MarketBeat, and ranked 155th out of 910 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingXeris Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialXeris Biopharma has a consensus price target of $12.00, representing about 40.7% upside from its current price of $8.53.Amount of Analyst CoverageXeris Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Xeris Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth328.57% Earnings GrowthEarnings for Xeris Biopharma are expected to grow by 328.57% in the coming year, from $0.07 to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -77.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -77.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 106.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xeris Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.01% of the float of Xeris Biopharma has been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 4.44.Change versus previous monthShort interest in Xeris Biopharma has recently decreased by 5.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.99 News SentimentXeris Biopharma has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Xeris Biopharma this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,847,219.00 in company stock.Percentage Held by Insiders4.35% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XERS Stock News HeadlinesXeris Biopharma (NASDAQ:XERS) Lowered to "Hold" Rating by Wall Street ZenSeptember 5 at 1:24 AM | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Insider Sells 5,000 SharesSeptember 2, 2026 | insidertrades.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | Investors Alley (Ad)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Hold" by AnalystsAugust 27, 2026 | americanbankingnews.comXeris Announces Details for XP-8121 Program Overview WebinarAugust 26, 2026 | businesswire.comXeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy OpportunityAugust 20, 2026 | seekingalpha.comWhy Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121August 16, 2026 | finance.yahoo.comInsider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 5,000 Shares of StockAugust 13, 2026 | insidertrades.comSee More Headlines XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $7.85 at the beginning of 2026. Since then, XERS shares have increased by 8.7% and is now trading at $8.53. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.19. The business earned $92.10 million during the quarter, compared to analyst estimates of $90.13 million. Xeris Biopharma had a negative net margin of 5.12% and a positive trailing twelve-month return on equity of 338.21%. Read the conference call transcript. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Top institutional investors of Xeris Biopharma include BlackRock Inc. (8.41%), Wellington Management Group LLP (1.30%), Legal & General Group Plc (1.10%) and Parkman Healthcare Partners LLC (0.99%). Insiders that own company stock include John Patrick Shannon Jr, Kevin Mcculloch, Steven Pieper, Beth Hecht, John Johnson, Jeffrey W Sherman, Marla Persky, Barbara-Jean A Bormann-Kennedy, Dawn Halkuff and James Aloysius Brady. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2026Today9/06/2026Status update9/09/2026H.C. Wainwright 28th Annual Global Investment Conference9/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 XERS's financial health is in the Green zone, according to TradeSmith. XERS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:XERS CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Price Target for Xeris Biopharma$12.00 High Price Target$18.00 Low Price Target$8.00 Potential Upside/Downside+40.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.11) Trailing P/E RatioN/A Forward P/E Ratio121.86 P/E GrowthN/ANet Income$550 thousand Net Margins-5.12% Pretax Margin-5.12% Return on Equity338.21% Return on Assets3.50% Debt Debt-to-Equity Ratio17.00 Current Ratio1.45 Quick Ratio1.02 Sales & Book Value Annual Sales$291.85 million Price / Sales5.33 Cash Flow$0.10 per share Price / Cash Flow85.16 Book Value$0.08 per share Price / Book106.63Miscellaneous Outstanding Shares182,320,000Free Float174,389,000Market Cap$1.56 billion OptionableOptionable Beta0.70 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:XERS) was last updated on 9/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
